Work

Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

Year: 2006

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v108.11.2837.2837

Authors: John C. Byrd, Ian W. Flinn, Khuda D. Khan, Thomas J. Kipps, Lea Aukerman, Judith Fox, Sandhya Girish, Serge Guzy, Sanela Bilic, Alan Solinger, Sherri Dort, Yongyu Wang, Deborah Hurst, Susan O’Brien

Institutions: The Ohio State University, Johns Hopkins University, Johns Hopkins Medicine, Johns Hopkins Hospital, St. Francis Hospital, University of California San Diego, XOMA (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2550696733

FWCI: 1.911

Cites:

Cited by: 18

Related to: 10